USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS

ABSTRACT

Use of compound of general formula (I), wherein R^1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, arylC_{1-6}alkoxy, $-CO_2R^4$, $-(CH_2)_nCN$, $-(CH_2)_nCONR^5R^6$, $-(CH_2)_nSO_2NR^5R^6$, C_{1-6}alkanolyamino$(CH_2)_n$, or C_{1-6}alkylsulphonylamino(CH_2)n; R^4 represents hydrogen, C_{1-6}alkyl or arylC_{1-6}alkyl; R^5 and R^6 each independently represent hydrogen or C_{1-6}alkyl, or R^5 and R^6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R^2 and R^3 each independently represent hydrogen, C_{1-6}alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-Ht_1-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositic s containing them are also described.